

INTERNATIONAL SEARCH REPORT

International Application No

PCT/AT2005/000107

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K38/00 A61K31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, WPI Data, PAJ, BIOSIS, FSTA, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/65935 A (VODOVOTZ YORAM; GAGE FREDERICK A) 13 September 2001 (2001-09-13) page 7, paragraph 5 - page 13, paragraph 1; claims 1-3	1-7
A	EP 0 853 944 A (BAXTER AKTIENGESELLSCHAFT; IMMUNO AKTIENGESELLSCHAFT) 22 July 1998 (1998-07-22) the whole document	1-7

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 July 2005

Date of mailing of the international search report

18. 10. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schönwasser, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/AT2005/000107

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	RICHARDSON G ET AL: "Potential therapeutic uses for S-nitrosothiols." CLINICAL SCIENCE (LONDON, ENGLAND : 1979) JAN 2002, vol. 102, no. 1, January 2002 (2002-01), pages 99-105, XP002338091 ISSN: 0143-5221 the whole document -----	1-7
A	CRANE MICHAEL S ET AL: "Novel role for low molecular weight plasma thiols in nitric oxide-mediated control of platelet function." THE JOURNAL OF BIOLOGICAL CHEMISTRY. 6 DEC 2002, vol. 277, no. 49, 6 December 2002 (2002-12-06), pages 46858-46863, XP002338092 ISSN: 0021-9258 the whole document -----	1-7
A	MEYER D J ET AL: "Kinetics and equilibria of S-nitrosothiol-thiol exchange between glutathione, cysteine, penicillamines and serum albumin" FEBS LETTERS 1994 NETHERLANDS, vol. 345, no. 2-3, 1994, pages 177-180, XP002338093 ISSN: 0014-5793 the whole document -----	1-7

INTERNATIONAL SEARCH REPORT

International application No.

AT2005/000107

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

SEE ADDITIONNAL SHEET

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-4, 6, 7 (partly); 5 (as a whole)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

The International Searching Authority has determined that this international application contains multiple (groups of) inventions, namely

1. Claims 1-4, 6, 7 (in part); 5 (in full)

pharmaceutical compound containing S-nitrosoalbumin as therapeutic protein and glutathione as thiol-group compound.

2. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitrosoalbumin as therapeutic protein and L-cysteine, N-acetyl cysteine, L-cysteinylglycine, gamma-glutamylcysteine or homocysteine as thiol-group compound.

3. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitrosoalbumin as therapeutic protein and penicillamine as thiol-group compound.

4. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitrosoalbumin as therapeutic protein and penicillamide as thiol-group compound.

5. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitrosoalbumin as therapeutic protein and captopril as thiol-group compound.

6. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitrosoalbumin as therapeutic protein and dehydrolipoic acid as thiol-group compound.

7. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso-orosomucoid as therapeutic protein and glutathione as thiol-group compound.

8. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso-orosomucoid as therapeutic protein and L-cysteine, N-acetyl cysteine, L-cysteinylglycine, gamma-glutamylcysteine or homocysteine as thiol-group compound.

9. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso-orosomucoid as therapeutic protein and penicillamine as thiol-group compound.

10. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso-orosomucoid as therapeutic protein and penicillamide as thiol-group compound.

11. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso-orosomucoid as therapeutic protein and captopril as thiol-group compound.

12. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso-orosomucoid as therapeutic protein and dehydrolipoic acid as thiol-group compound.

13. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso plasminogen activator as therapeutic protein and glutathione as thiol-group compound.

14. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso plasminogen activator as therapeutic protein and L-cysteine, N-acetyl cysteine, L-cysteinylglycine, gamma-glutamylcysteine or homocysteine as thiol-group compound.

15. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso plasminogen activator as therapeutic protein and penicillamine as thiol-group compound.

16. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso plasminogen activator as therapeutic protein and penicillamide as thiol-group compound.

17. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso plasminogen activator as therapeutic protein and captopril as thiol-group compound.

18. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso plasminogen activator as therapeutic protein and dehydrolipoic acid as thiol-group compound.

19. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso fibrinogen as therapeutic protein and glutathione as thiol-group compound.

20. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso fibrinogen as therapeutic protein and L-cysteine, N-acetyl cysteine, L-cysteinylglycine, gamma-glutamylcysteine or homocysteine as thiol-group compound.

21. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso fibrinogen as therapeutic protein and penicillamine as thiol-group compound.

22. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso fibrinogen as therapeutic protein and penicillamide as thiol-group compound.

23. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso fibrinogen as therapeutic protein and captopril as thiol-group compound.

24. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso fibrinogen as therapeutic protein and dehydrolipoic acid as thiol-group compound.

25. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso lys-plasminogen as therapeutic protein and glutathione as thiol-group compound.

26. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso lys-plasminogen as therapeutic protein and L-cysteine, N-acetyl cysteine, L-cysteinylglycine, gamma-glutamylcysteine or homocysteine as thiol-group compound.

27. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso lys-plasminogen as therapeutic protein and penicillamine as thiol-group compound.

28. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso lys-plasminogen as therapeutic protein and penicillamide as thiol-group compound.

29. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso lys-plasminogen as therapeutic protein and captopril as thiol-group compound.

30. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso lys-plasminogen as therapeutic protein and dehydrolipoic acid as thiol-group compound.

31. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso hemoglobin as therapeutic protein and glutathione as thiol-group compound.

32. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso hemoglobin as therapeutic protein and L-cysteine, N-acetyl cysteine, L-cysteinylglycine, gamma-glutamylcysteine or homocysteine as thiol-group compound.

33. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso hemoglobin as therapeutic protein and penicillamine as thiol-group compound.

34. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso hemoglobin as therapeutic protein and penicillamide as thiol-group compound.

35. Claims 1-4, 7 (in part)

pharmaceutical compound containing S-nitroso hemoglobin as
therapeutic protein and captopril as thiol-group compound.

36. Claims 1-4, 6, 7 (in part)

pharmaceutical compound containing S-nitroso hemoglobin as
therapeutic protein and dehydropoic acid as thiol-group
compound.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/AT2005/000107

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0165935	A	13-09-2001	AU	4190801 A		17-09-2001
EP 0853944	A	22-07-1998	AT	405135 B		25-05-1999
			AT	6897 A		15-10-1998
			DE	59811071 D1		06-05-2004
			US	6124255 A		26-09-2000